All In Biotech

Drug Trial Radar · NCT03384940

DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)

A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

86

Actual

Start

Feb 23, 2018

Primary completion

Aug 9, 2019

Study completion Nov 10, 2020

Sponsor

Lead sponsor
Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
Daiichi Sankyo; AstraZeneca
First posted
Dec 28, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.

Conditions

  • Colorectal Neoplasm

Interventions

  • DS-8201aDrug

    DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Best Objective Response Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal CancerTime frame: Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 18 months post-dose
  2. Number of Participants With Objective Response Rate Based on Independent Central Review (Confirmed and Unconfirmed) Following DS-8201a Treatment in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Advanced Colorectal CancerTime frame: Baseline up to withdrawal of consent, progressive disease, or unacceptable toxicity (whichever occurs first), up to 18 months post-dose

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • City of Hope Medical Center

    Duarte, California

  • University of Southern California

    Los Angeles, California

  • UCLA Health

    Santa Monica, California

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Greenville Health System Cancer Institute

    Greenville, South Carolina

  • West Cancer Center

    Germantown, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • MD Anderson Cancer Center, University of Texas

    Houston, Texas

  • Fondazione IRCCS - Istituto Nazionale dei Tumori

    Milan, Italy

  • Università degli studi della Campania L.Vanvitelli

    Naples, Campania, Italy

  • Oncology Institute Veneto IOV-IRCCS

    Padova, Ferrara, Italy

  • ASST Grande Ospedale Metropolitano Niguarda

    Milan, Lombardo, Italy

  • National Hospital Organization Kyushu Cancer Center

    Fukuoka, Japan

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, Ehime, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, Japan

  • Kindai University Hospital

    Ōsaka-sayama, Osaka, Japan

  • The Cancer Institute Hospital of Japanese Foundation for Cancer Research

    Koto-Ku, Tokyo, Japan

  • Hospital Universitari Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitari Clinic de Barcelona

    Barcelona, Spain

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain

  • Royal Marsden Institute (Chelsea)

    Chelsea, London, England, United Kingdom

  • Royal Marsden Institute (Sutton)

    Sutton, Surrey, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.